Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
Question In patients with combined psychotic and depressive syndrome, is risperidone effective compared with haloperidol plus amitriptyline for improving psychotic and depressive symptoms?
6 week randomised, double blind, controlled trial.
Clinical centres in Austria and Germany*.
123 patients (62% women) who were 19 to 63 years of age; had comorbid major depression with paranoid or hallucinatory symptoms, or both; scored ≥60 points on the Positive and Negative Syndrome Scale (PANSS) with ≥4 points scored on the positive symptoms subscale; and scored ≥15 points on the Bech-Rafaelsen Melancholia Scale (BRMES) with ≥3 points scored on its depression item. Diagnoses according to DSM-III-R were major depression with psychotic features (31%); schizoaffective disorder, depressive type (52%); schizoaffective disorder, bipolar type (2%); and schizophrenia or schizophreniform disorder with major depressive symptoms (15%). 14% of patients were also diagnosed with an Axis II disorder. Exclusion criteria included high suicidal risk and substantial physical disorder.
Patients were allocated to a fixed dose escalation schedule of risperidone, range 2 to 12 mg/day (n=62); or haloperidol, range 2.5 to 15 mg/day, plus amitriptyline, range 50 to 300 mg/day (n=61). Daily medication doses were altered in response to side effects and clinical response.
Main outcome measures
Changes in psychotic and depressive symptoms, presence of extrapyramidal symptoms, and adverse effects at 6 weeks.
The difference in dropout rate between treatments was not statistically significant (32% for risperidone v 21% for haloperidol and amitriptyline, p=0.17). Haloperidol and amitriptyline led to a greater decrease than risperidone in psychotic symptoms (mean decrease in Brief Psychiatric Rating Scale score 25.2 v 17.6, p=0.009) and depressive symptoms (mean decrease in BRMES score 15.8 v 10.5, p=0.002). Patients who were allocated to risperidone developed more extrapyramidal symptoms than those who were allocated to haloperidol and amitriptyline according to the total Extrapyramidal Symptom Rating Scale (EPSR) score (mean increase 6.2 v 3.2, p=0.03), mainly because of a higher shift in the parkinsonian subscale score of the EPSR (mean increase 5.8 v 2.9, p=0.03). The difference between treatments in the number of patients who reported adverse events was not statistically significant (66% for risperidone v 75% for haloperidol and amitriptyline; p=0.35).
In patients who had a combined depressive and psychotic syndrome, haloperidol and amitriptyline led to greater reductions in depressive and psychotic symptoms than risperidone. Patients who received risperidone had more extrapyramidal symptoms than those who received haloperidol and amitrypriline. No substantial difference in other adverse events existed between treatments.
Müller-Siecheneder et al developed 2 strands of thought on the management of patients with psychotic and depressive symptoms. Firstly, they adopted a target syndrome definition of psychosis and depression that allowed for the amalgamation of patients meeting a range of DSM-III-R diagnoses under 1 functional heading. Secondly, they tested their previous clinical observation that risperidone, an effective antipsychotic agent,1 may have a clinically useful antidepressant effect.2
A previous meta-analysis suggested that an antidepressant and antipsychotic combination may not confer any additional advantage to the treatment of depressed subjects with delusions.3
The findings of this study show that it is unwise to substitute risperidone for the amitriptyline and haloperidol combination in patients who have the target syndrome of psychotic and depressive symptoms. Although the reduction in scores on positive symptoms of the PANSS did not differ substantially between the treatment groups, those treated with the combination of drugs had a greater reduction of scores on the negative symptoms and general psychopathology scales. Subgroup analysis showed that patients with major depression and psychotic features (DSM-III-R category 295.24/34) respond better to the combination treatment than to risperidone. Whether risperidone may be prescribed instead for patients with DSM-III-R schizophrenic symptoms and depression needs further elucidation.
The patients who received the combination of drugs were also less likely to show an increase in parkinsonian symptoms than those who received risperidone, although as the authors note, the dose of risperidone prescribed may have been higher than current recommendations.1
Source of funding: Janssen Research Foundation.
For correspondence: Dr O Benkert, principal investigator and senior author of the publication, Department of Psychiatry, University of Mainz, Untere Zahlbacher Straβe 8, Mainz, Germany D-55131. Fax +49 61 31 229974.
↵* Information provided by author.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.